The EMA’s Committee for Medicinal Products for Human Use is poised to support Boehringer Ingelheim’s Jascayd (nerandomilast) as a potential replacement for Ofev (nintedanib) amid the approach of generic competition. The same update also included a positive recommendation for Novartis’s Vijoice (alpelisib) in PIK3CA-related overgrowth spectrum disorders, alongside additional positive signals for antibody-drug conjugate and formulation reviews.